Aurobindo Pharma Shares Dip on Clarification Over $5.5 Billion Zentiva Deal

Aurobindo Pharma shares fell on Wednesday after the company clarified that reports of an imminent $5.5 billion acquisition of Zentiva were premature. While confirming it regularly evaluates strategic opportunities, including acquisitions, the firm stated no definitive decision has been made by the board regarding the Zentiva transaction and no binding agreement exists. The potential deal, if completed, would be the largest ever by an Indian pharma company, surpassing major past deals like Daiichi Sankyo’s acquisition of Ranbaxy. Zentiva, a leading generics player in Eastern Europe, would significantly strengthen Aurobindo’s presence in high-growth markets like the Czech Republic, Romania, and Slovakia—where demand for biosimilars is rising post-patent expiries. Unlike the volatile US generics market, Eastern Europe’s government-driven procurement offers more stable returns, aligning well with Aurobindo’s strategy. The company already earns the highest European revenue among Indian pharma firms. Aurobindo reaffirmed its commitment to SEBI’s disclosure norms, promising timely updates if any material development occurs. While the market reacted negatively to the uncertainty, the long-term strategic rationale behind the potential acquisition remains compelling.